Investor Presentation • Jan 24, 2022
Investor Presentation
Open in ViewerOpens in native device viewer
Certain statements in this slide show, including those addressing the Company's beliefs, plans, objectives, estimates or expectations of possible future results or events, are forward-looking statements. Forward-lookingstatements involve known or unknown risks, including general economic and business conditions, and conditions in the industry we operate and may be affected should our assumptions turn out to be inaccurate. Consequently, no forward-looking statement can be guaranteed and actual future results, performance, or achievements may vary materially from those expressed or implied by such forward-looking statements. The Company undertakes no obligation about the contents nor to update the forward-looking statements to reflect events or circumstances that may arise after the date hereof.
Hi-Tech industrial group providing laser solutions with proprietary technologies and know how developed over 40 years
Listed on Milan's Stock Exchange Star segment since year 2000
Active worldwide on several laser application segments and markets…
…progressively widening its worldwide presence achieving continuous growth over the years
Our energy based systems improve people's well-being and life quality.
In the surgical sector, our minimally invasive technology systems minimize pain, side effects and risks of surgical procedures andhospitalization days.
In the aesthetic sector, our systems satisfy the growing desire of individuals to improve their appearance also reducing pathological or painful imperfections
Our laser systems preserve artworks of the universal heritage of our communities.
Our laser cutting and marking systems reduce the environmental impact of manufacturing processes minimizing waste, fumes generated by the process, use of chemical additives, also allowing to eliminate the need for inks, solvents or glues within the process.
Medical Aesthetics: Market Overview (pre-Covid)
Source: Daniel Associates
| 2 0 1 8 |
2 0 2 4 |
C a g r |
||
|---|---|---|---|---|
| l h d i i F A P t t t a c a e s e c s r o u c s |
1. 8 3 1 |
3. 6 3 8 |
1 0, 7 % |
|
| d i i B C D t o y o n o u r n g e v c e s |
1. 7 0 8 |
3. 1 7 2 |
1 0, 3 % |
|
| l i C I t t o s m e c m p a n s |
1. 3 2 1 |
2. 4 1 5 |
% 1 0, 0 |
|
| h d d l i i i i i P t s c a n- s p e n c e c o s m o c e u c a s |
||||
| d k i a n s n |
1. 1 0 4 |
1. 9 0 3 |
1 0, 2 % |
|
| k h S i i i A D t t n e s e c e v c e s |
9 3 8 |
1. 7 6 2 |
1 0, 2 % |
|
| h d d l h i i i i P s c a n- s p e n c e e y e a s |
||||
| d t p r o u c s |
9 1 0 |
1. 5 5 1 |
1 0, 0 % |
|
| l d i i H a r r e m o v a e v c e s |
7 8 3 |
1. 4 3 2 |
% 1 0, 0 |
|
| l d i T t t a o o r e m o v a e v c e s |
8 7 |
1 5 3 |
% 9, 9 |
|
| h d l f d i T t t r e a p r o u c s |
7 3 |
1 2 5 |
9, 8 % |
|
| l l d i i N t t t a r e a m e n a s e r e v c e s |
6 1 |
1 1 0 |
9, 5 % |
Sou : Da nie l As iate rce soc s |
| 8 8 1 6 |
1 6. 2 6 1 |
| 2 0 1 8 |
2 0 2 4 |
C a g r |
|
|---|---|---|---|
| h N A i t o r m e r c a |
3. 1 4 7 |
5. 6 8 9 |
9, 9 % |
| E u r o p e |
1. 9 5 8 |
3. 4 8 0 |
% 9, 4 |
| f A i P i i s a a c c |
2. 3 4 3 |
4 6 3 5 |
1 1, 6 % |
| d d l f i & i M E A t e a s r c a |
8 2 2 |
1. 4 9 2 |
% 9, 8 |
| L i A i t a n m e r c a |
4 5 7 |
9 6 5 |
9, 4 % |
| 8 8 1 6 |
1 6. 2 6 1 |
The global Medical Laser Market size was valued @ USD 4,37 billion in 2019 and is projected to reach USD 10,57 billion by 2027, exhibiting a CAGR of 13,9% during the forecast period
The global energy based aesthetic devices market is estimated at \$ 4.0 B today and is projected to grow \$ 8.4B by 2021 with a 12%CAGR
Laser systems increasingly adopted in high quality manufacturing for uniqueness, flexibility, environment friendliness, productivity
"The global industrial lasers systems market size was valued at \$20,120.2 million in 2018, and is projected to reach \$36,510.6 million by 2026, growing at a CAGR of 7.5% from 2019 to 2026"
Improved capabilities of our body contouring flagship system
An effective set of unique combinations of superluminescent led matrices with Tens and EMS
High intensity magnetic fields for muscles stimulation
Micro alveolar stimulation
Unique high end system for laser hair removal
The ultimate multi application and multi technology platform
The system for neocollagenesis and tissue regeneration
Discovery Pico DermDesigned for Asian skins
Chrome StationThree wavelengths multi platform
23
Urology
One of two worldwide players in high power medical fiber lasers
Our novel disruptive technology for the most effective stones micro fragmentation
Novel CO2 device for dermatology and gynecology featuring an additional 1540nm laser source
MiS (MLS Family) For degenerative neuropathies
10 kW Average power in 2020 sales bookings40 kW systemsto come in 2021
Laser cutting systems offer in China
| '0 E 0 0 r o u |
/ / 3 0 0 9 1 9 |
% | / / 3 0 0 9 2 0 |
% | / / 3 0 0 9 2 1 |
% | % C a g r |
|---|---|---|---|---|---|---|---|
| d d i t n a e u u |
d d i t n a e u u |
d d i t n a e u u |
|||||
| d l i M e c a |
1 7 0. 7 6 1 |
% 6 0, 4 |
1 5 9. 7 4 2 |
% 5 9, 6 |
2 2 0. 4 7 6 |
% 5 4, 4 |
% 1 3, 6 |
| d l I i t n s r a u |
1 1 2. 1 8 7 |
3 9, 6 % |
1 0 8. 4 2 5 |
4 0, 4 % |
1 8 4. 8 2 4 |
4 5, 6 % |
2 8, 4 % |
| R e v e n u e s |
2 8 2. 9 4 8 |
% 1 0 0, 0 |
2 6 8. 1 6 8 |
% 1 0 0, 0 |
4 0 5. 3 0 0 |
% 1 0 0, 0 |
% 1 9, 7 |
| G i r o s s m a r g n |
1 1 1. 1 4 5 |
3 9, 3 % |
9 0 4 4 7 |
3 2 % 5, |
0 2 0 3 1 5 |
3 % 7, 1 |
6, 2 % 1 |
| O i E t p e r a n g p e n s e s x |
3 1. 0 3 2 |
% 1 1, 0 |
2 3. 9 7 8 |
% 8, 9 |
3 3. 9 8 4 |
% 8, 4 |
% 4, 6 |
| f f S t a e s p e n s e s |
4 7. 4 9 7 |
% 1 6, 8 |
4 4 6 5 9 |
% 1 6, 7 |
6 0 5 5 6 |
% 1 4, 9 |
% 1 2, 9 |
| E B I T D A |
3 2. 6 1 6 |
% 1 1, 5 |
2 5. 7 7 0 |
% 9, 6 |
5 5. 6 6 3 |
% 1 3, 7 |
% 3 0, 6 |
| l D t. e p r., a m o r a c c r u a s , |
6. 1 7 1 |
% 2, 2 |
7. 6 3 5 |
% 2, 8 |
1 1. 0 8 6 |
% 2, 7 |
% 3 4, 0 |
| E B I T |
2 6. 4 4 5 |
9, 3 % |
1 8. 1 3 5 |
6, 8 % |
4 4 5 7 7 |
1 1, 0 % |
2 9, 8 % |
| f ( h ) N i i t e n a n c. n c o m e c a r g e s |
1. 1 6 6 |
% 0, 4 |
( ) 9 8 1 |
% 0, 4 - |
1. 1 5 6 |
% 0, 3 |
% 0, 4 - |
| h ( ) i O t t e r n c o m e e x p e n s e n e |
9 | % 0, 0 |
( ) 2 7 9 |
% 0, 1 - |
( ) 1 7 1 |
% 0, 0 |
|
| E B T |
2 7. 6 2 1 |
9, 8 % |
1 6. 8 7 5 |
6, 3 % |
4 5. 5 6 2 |
1 1, 2 % |
2 8, 4 % |
| / / 3 1 1 2 2 0 |
/ / 3 0 0 9 2 1 |
Net financial position
unaudited64.168 74.743
| l l i M t u p e s |
||||
|---|---|---|---|---|
| k h l d 's h i S E t t o c o e r q p e r s a r e u y |
3 5 , |
|||
| / i k l d j V A P B r c e o o a u e |
4 1 , |
|||
| / ( ) % E V E B I T 9 0 E B I T |
1 9 5 , |
|||
| / ( ) l l S 9 0 % S E V a e s a e s |
2 1 , |
|||
| l. k C E E M t n a r e a p |
3 9 @ 1 1 4 , |
€ 2 2 1 4 , |
||
| f l i i i i N t t e n a n c a p o s o n |
@ 7 4 7 , |
/ / 3 0 0 9 2 1 |
||
| / l l i i i F t t t n a n c a n v e s m e n s m e r m |
8 3 @ 1 , |
/ / 3 0 0 9 2 1 |
||
| i l E V t n e r p r s e a u e |
1 0 4 1, 8 |
Comparables
| in m ln Am nts ou |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| h , Se 3 0 2 0 2 1 t. t p |
ice Pr |
Re ve nu e |
% Va r. |
E B I T |
% E B I T |
M K. Ca p. |
E V |
/ les E V Sa |
/ E V E B I T |
/ k P Bo o |
| / d ica l he ic Me Ae t t s |
Re v. |
( *) |
( *) |
lu Va e |
||||||
| Cu te ra |
\$ 3 4, 9 4 |
\$ 1 4 6 |
4 9 % |
\$ 7 |
% 5 |
\$ 6 3 0 |
\$ 4 8 2 |
2, 5 |
2, 8 5 |
1 1, 4 |
| de In Mo |
\$ 4 4, 9 2 |
\$ 2 4 7 |
8 9 % |
\$ 1 1 3 |
4 6 % |
\$ 3. 4 3 0 |
\$ 3. 0 4 7 |
9, 2 |
2 0, 2 |
8, 9 |
| Ve nu s |
\$ 1, 5 6 |
\$ 7 3 |
4 0 % |
\$ ( ) 1 1 |
-1 5 % |
\$ 9 4 |
\$ 1 5 5 |
1, 6 |
n.a | 3, 3 |
| isr d ica l ( ** ) S Me am |
\$ 1, 1 4 |
\$ 1 2 5 |
7 5 % |
\$ 2 1 |
1 7 % |
\$ 5 3 1 |
\$ 4 3 6 |
1, 7 |
1 0, 2 |
1, 5 |
| Lu ic tro n |
€ 1 4, 2 9 |
€ 8 8 |
5 7 % |
€ 1 7 |
1 9 % |
€ 3 7 0 |
€ 3 3 6 |
2, 9 |
1 5, 0 |
4, 3 |
| du ia l In tr s |
||||||||||
| ho ics I P G P Co to n |
\$ 1 5 3, 5 8 |
\$ 1. 0 9 6 |
% 2 7 |
\$ 2 8 2 |
% 2 6 |
\$ 8. 5 2 0 |
\$ 7. 0 4 1 |
4, 8 |
1 8, 7 |
3, 1 |
| im du ie Pr In tr a s |
€ 9, 1 7 4 |
€ 2 8 4 |
2 2 % |
€ 6 |
2 % |
€ 2 0 7 |
€ 3 0 9 |
0, 8 |
3 7, 4 |
3 1, |
| 's Ha La n se r |
¥ 4 8, 3 3 |
¥ 1 1. 8 8 5 |
3 5 % |
¥ 1. 5 4 4 |
1 3 % |
¥ 5 1. 9 7 0 |
¥ 5 3. 9 2 2 |
3, 4 |
2 6, 2 |
4, 7 |
| ( ** ) By ic tro s n |
C H F 1. 2 7 4 |
C H F 4 4 1 |
1 8 % |
C H F 3 0 |
7 % |
C H F 2. 3 1 0 |
C H F 1. 8 3 6 |
2, 1 |
3 0, 3 |
2, 9 |
| ( ) l. E En 1 |
2 2 € 1 4, |
0 € 4 5 |
% 5 1 |
€ 4 5 |
% 1 1 |
3 € 1. 1 5 |
0 2 € 1. 4 |
2, 1 |
9, 1 5 |
4, 1 |
(1) EV and multiplies as for previous slide
(*) Revenue,Ebit and earnings annualized
(**) Data on June 30th, 2021
Enrico ROMAGNOLI Investor Relations Managertel. +39 055-8826807E-mail: [email protected]
Financial Communication, IR and Press Office Bianca FERSINI MASTELLONI - [email protected] Silvia MARONGIU - [email protected] Tel. +39 06-69923324
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.